A registry of patients with severe deficiency of alpha1-antitrypsin

Design and methods

M. D. Schluchter, A. F. Barker, Ronald Crystal, R. A. Robbins, J. M. Stocks, J. K. Stoller, M. C. Wu, Z. Bengali, C. E. Vreim, A. Rothgeb, G. L. Snider, K. Detre, H. Y. Reynolds, M. S. Tockman, J. Wittes, A. S. Buist, B. Burrows, A. Cohen, R. J. Fallat

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

The Registry of Patients with Severe Deficiency of Alpha1-Antitrypsin (AIAT) is a multicenter natural history study, with 37 participating clinical centers in the United States (36 centers) and Canada (1 center). The study has enrolled 1,129 individuals aged ≥18 years with severe deficiency of AIAT (serum level ≤11 μM), and will follow them longitudinally for up to 7 years, characterizing the clinical course of the disease, regardless of whether they are receiving augmentation therapy. Primary outcomes of interest are the yearly decline in FEV1 and mortality. This article describes the design and structure of the Registry.

Original languageEnglish
Pages (from-to)1223-1232
Number of pages10
JournalChest
Volume106
Issue number4
Publication statusPublished - 1 Jan 1994
Externally publishedYes

Fingerprint

Registries
Natural History
Canada
Mortality
Serum
Therapeutics

Keywords

  • alpha-antitrypsin
  • augmentation therapy
  • decline in lung function
  • design of studies
  • emphysema
  • longitudinal studies
  • registries
  • replacement therapy

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Schluchter, M. D., Barker, A. F., Crystal, R., Robbins, R. A., Stocks, J. M., Stoller, J. K., ... Fallat, R. J. (1994). A registry of patients with severe deficiency of alpha1-antitrypsin: Design and methods. Chest, 106(4), 1223-1232.

A registry of patients with severe deficiency of alpha1-antitrypsin : Design and methods. / Schluchter, M. D.; Barker, A. F.; Crystal, Ronald; Robbins, R. A.; Stocks, J. M.; Stoller, J. K.; Wu, M. C.; Bengali, Z.; Vreim, C. E.; Rothgeb, A.; Snider, G. L.; Detre, K.; Reynolds, H. Y.; Tockman, M. S.; Wittes, J.; Buist, A. S.; Burrows, B.; Cohen, A.; Fallat, R. J.

In: Chest, Vol. 106, No. 4, 01.01.1994, p. 1223-1232.

Research output: Contribution to journalArticle

Schluchter, MD, Barker, AF, Crystal, R, Robbins, RA, Stocks, JM, Stoller, JK, Wu, MC, Bengali, Z, Vreim, CE, Rothgeb, A, Snider, GL, Detre, K, Reynolds, HY, Tockman, MS, Wittes, J, Buist, AS, Burrows, B, Cohen, A & Fallat, RJ 1994, 'A registry of patients with severe deficiency of alpha1-antitrypsin: Design and methods', Chest, vol. 106, no. 4, pp. 1223-1232.
Schluchter MD, Barker AF, Crystal R, Robbins RA, Stocks JM, Stoller JK et al. A registry of patients with severe deficiency of alpha1-antitrypsin: Design and methods. Chest. 1994 Jan 1;106(4):1223-1232.
Schluchter, M. D. ; Barker, A. F. ; Crystal, Ronald ; Robbins, R. A. ; Stocks, J. M. ; Stoller, J. K. ; Wu, M. C. ; Bengali, Z. ; Vreim, C. E. ; Rothgeb, A. ; Snider, G. L. ; Detre, K. ; Reynolds, H. Y. ; Tockman, M. S. ; Wittes, J. ; Buist, A. S. ; Burrows, B. ; Cohen, A. ; Fallat, R. J. / A registry of patients with severe deficiency of alpha1-antitrypsin : Design and methods. In: Chest. 1994 ; Vol. 106, No. 4. pp. 1223-1232.
@article{50c3b431fd6a4bffa6210c6d0c197e2f,
title = "A registry of patients with severe deficiency of alpha1-antitrypsin: Design and methods",
abstract = "The Registry of Patients with Severe Deficiency of Alpha1-Antitrypsin (AIAT) is a multicenter natural history study, with 37 participating clinical centers in the United States (36 centers) and Canada (1 center). The study has enrolled 1,129 individuals aged ≥18 years with severe deficiency of AIAT (serum level ≤11 μM), and will follow them longitudinally for up to 7 years, characterizing the clinical course of the disease, regardless of whether they are receiving augmentation therapy. Primary outcomes of interest are the yearly decline in FEV1 and mortality. This article describes the design and structure of the Registry.",
keywords = "alpha-antitrypsin, augmentation therapy, decline in lung function, design of studies, emphysema, longitudinal studies, registries, replacement therapy",
author = "Schluchter, {M. D.} and Barker, {A. F.} and Ronald Crystal and Robbins, {R. A.} and Stocks, {J. M.} and Stoller, {J. K.} and Wu, {M. C.} and Z. Bengali and Vreim, {C. E.} and A. Rothgeb and Snider, {G. L.} and K. Detre and Reynolds, {H. Y.} and Tockman, {M. S.} and J. Wittes and Buist, {A. S.} and B. Burrows and A. Cohen and Fallat, {R. J.}",
year = "1994",
month = "1",
day = "1",
language = "English",
volume = "106",
pages = "1223--1232",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "4",

}

TY - JOUR

T1 - A registry of patients with severe deficiency of alpha1-antitrypsin

T2 - Design and methods

AU - Schluchter, M. D.

AU - Barker, A. F.

AU - Crystal, Ronald

AU - Robbins, R. A.

AU - Stocks, J. M.

AU - Stoller, J. K.

AU - Wu, M. C.

AU - Bengali, Z.

AU - Vreim, C. E.

AU - Rothgeb, A.

AU - Snider, G. L.

AU - Detre, K.

AU - Reynolds, H. Y.

AU - Tockman, M. S.

AU - Wittes, J.

AU - Buist, A. S.

AU - Burrows, B.

AU - Cohen, A.

AU - Fallat, R. J.

PY - 1994/1/1

Y1 - 1994/1/1

N2 - The Registry of Patients with Severe Deficiency of Alpha1-Antitrypsin (AIAT) is a multicenter natural history study, with 37 participating clinical centers in the United States (36 centers) and Canada (1 center). The study has enrolled 1,129 individuals aged ≥18 years with severe deficiency of AIAT (serum level ≤11 μM), and will follow them longitudinally for up to 7 years, characterizing the clinical course of the disease, regardless of whether they are receiving augmentation therapy. Primary outcomes of interest are the yearly decline in FEV1 and mortality. This article describes the design and structure of the Registry.

AB - The Registry of Patients with Severe Deficiency of Alpha1-Antitrypsin (AIAT) is a multicenter natural history study, with 37 participating clinical centers in the United States (36 centers) and Canada (1 center). The study has enrolled 1,129 individuals aged ≥18 years with severe deficiency of AIAT (serum level ≤11 μM), and will follow them longitudinally for up to 7 years, characterizing the clinical course of the disease, regardless of whether they are receiving augmentation therapy. Primary outcomes of interest are the yearly decline in FEV1 and mortality. This article describes the design and structure of the Registry.

KW - alpha-antitrypsin

KW - augmentation therapy

KW - decline in lung function

KW - design of studies

KW - emphysema

KW - longitudinal studies

KW - registries

KW - replacement therapy

UR - http://www.scopus.com/inward/record.url?scp=0027941322&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027941322&partnerID=8YFLogxK

M3 - Article

VL - 106

SP - 1223

EP - 1232

JO - Chest

JF - Chest

SN - 0012-3692

IS - 4

ER -